Mechanism and treatment of polycystic ovary syndrome with nonalcoholic fatty liver disease
10.3969/j.issn.1001-5256.2022.03.035
- VernacularTitle:多囊卵巢综合征合并非酒精性脂肪性肝病的机制与治疗
- Author:
Tingting QIN
1
;
Ruihua ZHANG
1
;
Yu ZHANG
2
;
Xiaodong WEI
3
;
Xiaoyu WEN
1
Author Information
1. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China
2. Department of Pediatric Endocrinology, Genetics, and Metabolism, The First Hospital of Jilin University, Changchun 130021, China
3. School of Basic Medical Sciences, Jilin University, Changchun 130000, China
- Publication Type:Reviews
- Keywords:
Non-alcoholic Fatty Liver Disease;
Polycystic Ovary Syndrome;
Pathologic Processes
- From:
Journal of Clinical Hepatology
2022;38(3):660-665
- CountryChina
- Language:Chinese
-
Abstract:
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age, with the clinical manifestations of oligomenorrhea or amenorrhea, hyperandrogenism, and anovulatory infertility, and it is often accompanied by metabolic disorders such as obesity, insulin resistance, hyperinsulinemia, and glucose and lipid metabolism disorders. Women with PCOS often have nonalcoholic fatty liver disease (NAFLD) and other metabolic-associated diseases, and PCOS and NAFLD are related in terms of pathogenesis and treatment. This article reviews the research advances in PCOS with NAFLD in recent years.
